Anti-Tuberculosis Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030
It will take 2-3 business days to deliver the report upon receipt the order if any customization is not there.
Anti-Tuberculosis Therapeutics Trends and Forecast
The future of the global anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030 with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Anti-Tuberculosis Therapeutics by Segment
The study includes a forecast for the global anti-tuberculosis therapeutics by type, drug classes, end use, and region.
Anti-Tuberculosis Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies anti-tuberculosis therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the anti-tuberculosis therapeutics companies profiled in this report include-
Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.
Within this market, hospitals will remain the largest segment due to .
APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.
Features of the Global Anti-Tuberculosis Therapeutics Market
Market Size Estimates: Anti-tuberculosis therapeutics market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Anti-tuberculosis therapeutics market size by type, drug classes, end use, and region in terms of value ($B).
Regional Analysis: Anti-tuberculosis therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, drug classes, end uses, and regions for the anti-tuberculosis therapeutics market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the anti-tuberculosis therapeutics market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q.1 What is the anti-tuberculosis therapeutics market size?
Answer: The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030.
Q.2 What is the growth forecast for anti-tuberculosis therapeutics market?
Answer: The global anti-tuberculosis therapeutics market is expected to grow with a CAGR of 7.1% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the anti-tuberculosis therapeutics market?
Answer: The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.
Q4. What are the major segments for anti-tuberculosis therapeutics market?
Answer: The future of the anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.
Q5. Who are the key Anti-Tuberculosis Therapeutics Market companies?
Answer: Some of the key anti-tuberculosis therapeutics companies are as follows:
Answer: Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.
Q7. In anti-tuberculosis therapeutics market, which region is expected to be the largest in next 5 years?
Answer: APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the anti-tuberculosis therapeutics market by type (active TB, latent LB, and others), drug classes (isoniazid, rifampin, ethambutol, pyrazinamide, fluoroquinolones, bedaquiline, amynoglycosides, thioamides, cyclic peptides, and others), end use (hospitals, specialty clinics, homecare, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Anti-Tuberculosis Therapeutics Market, Anti-Tuberculosis Therapeutics Market Size, Anti-Tuberculosis Therapeutics Market Growth, Anti-Tuberculosis Therapeutics Market Analysis, Anti-Tuberculosis Therapeutics Market Report, Anti-Tuberculosis Therapeutics Market Share, Anti-Tuberculosis Therapeutics Market Trends, Anti-Tuberculosis Therapeutics Market Forecast, Anti-Tuberculosis Therapeutics Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
Anti-Tuberculosis Therapeutics Trends and Forecast
The future of the global anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030 with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Anti-Tuberculosis Therapeutics by Segment
The study includes a forecast for the global anti-tuberculosis therapeutics by type, drug classes, end use, and region.
Anti-Tuberculosis Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:
- Active TB
- Latent TB
- Others
- Isoniazid
- Rifampin
- Ethambutol
- Pyrazinamide
- Fluoroquinolones
- Bedaquiline
- Amynoglycosides
- Thioamides
- Cyclic Peptides
- Others
- Hospitals
- Specialty Clinics
- Homecare
- Others
- North America
- Europe
- Asia Pacific
- The Rest of the World
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies anti-tuberculosis therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the anti-tuberculosis therapeutics companies profiled in this report include-
- Lupin
- Macleods
- Otsuka
- Johnson & Johnson
- Sequella
- Novartis
- Akorn
- Fresenius Se
- Viatris
Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.
Within this market, hospitals will remain the largest segment due to .
APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.
Features of the Global Anti-Tuberculosis Therapeutics Market
Market Size Estimates: Anti-tuberculosis therapeutics market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Anti-tuberculosis therapeutics market size by type, drug classes, end use, and region in terms of value ($B).
Regional Analysis: Anti-tuberculosis therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, drug classes, end uses, and regions for the anti-tuberculosis therapeutics market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the anti-tuberculosis therapeutics market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q.1 What is the anti-tuberculosis therapeutics market size?
Answer: The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030.
Q.2 What is the growth forecast for anti-tuberculosis therapeutics market?
Answer: The global anti-tuberculosis therapeutics market is expected to grow with a CAGR of 7.1% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the anti-tuberculosis therapeutics market?
Answer: The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.
Q4. What are the major segments for anti-tuberculosis therapeutics market?
Answer: The future of the anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.
Q5. Who are the key Anti-Tuberculosis Therapeutics Market companies?
Answer: Some of the key anti-tuberculosis therapeutics companies are as follows:
- Lupin
- Macleods
- Otsuka
- Johnson & Johnson
- Sequella
- Novartis
- Akorn
- Fresenius SE
- Viatris
Answer: Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.
Q7. In anti-tuberculosis therapeutics market, which region is expected to be the largest in next 5 years?
Answer: APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the anti-tuberculosis therapeutics market by type (active TB, latent LB, and others), drug classes (isoniazid, rifampin, ethambutol, pyrazinamide, fluoroquinolones, bedaquiline, amynoglycosides, thioamides, cyclic peptides, and others), end use (hospitals, specialty clinics, homecare, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Anti-Tuberculosis Therapeutics Market, Anti-Tuberculosis Therapeutics Market Size, Anti-Tuberculosis Therapeutics Market Growth, Anti-Tuberculosis Therapeutics Market Analysis, Anti-Tuberculosis Therapeutics Market Report, Anti-Tuberculosis Therapeutics Market Share, Anti-Tuberculosis Therapeutics Market Trends, Anti-Tuberculosis Therapeutics Market Forecast, Anti-Tuberculosis Therapeutics Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
1. EXECUTIVE SUMMARY
2. GLOBAL ANTI-TUBERCULOSIS THERAPEUTICS MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Anti-Tuberculosis Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Anti-Tuberculosis Therapeutics Market by Type
3.3.1: Active TB
3.3.2: Latent TB
3.3.3: Others
3.4: Global Anti-Tuberculosis Therapeutics Market by Drug Classes
3.4.1: Isoniazid
3.4.2: Rifampin
3.4.3: Ethambutol
3.4.4: Pyrazinamide
3.4.5: Fluoroquinolones
3.4.6: Bedaquiline
3.4.7: Amynoglycosides
3.4.8: Thioamides
3.4.9: Cyclic Peptides
3.5: Global Anti-Tuberculosis Therapeutics Market by End Use
3.5.1: Hospitals
3.5.2: Specialty Clinics
3.5.3: Homecare
3.5.4: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Anti-Tuberculosis Therapeutics Market by Region
4.2: North American Anti-Tuberculosis Therapeutics Market
4.2.2: North American Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
4.3: European Anti-Tuberculosis Therapeutics Market
4.3.1: European Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
4.3.2: European Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
4.4: APAC Anti-Tuberculosis Therapeutics Market
4.4.1: APAC Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
4.4.2: APAC Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
4.5: ROW Anti-Tuberculosis Therapeutics Market
4.5.1: ROW Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
4.5.2: ROW Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Type
6.1.2: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Drug Classes
6.1.3: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by End Use
6.1.4: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Region
6.2: Emerging Trends in the Global Anti-Tuberculosis Therapeutics Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Anti-Tuberculosis Therapeutics Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Anti-Tuberculosis Therapeutics Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Lupin
7.2: Macleods
7.3: Otsuka
7.4: Johnson & Johnson
7.5: Sequella
7.6: Novartis
7.7: Akorn
7.8: Fresenius SE
7.9: Viatris
2. GLOBAL ANTI-TUBERCULOSIS THERAPEUTICS MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Anti-Tuberculosis Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Anti-Tuberculosis Therapeutics Market by Type
3.3.1: Active TB
3.3.2: Latent TB
3.3.3: Others
3.4: Global Anti-Tuberculosis Therapeutics Market by Drug Classes
3.4.1: Isoniazid
3.4.2: Rifampin
3.4.3: Ethambutol
3.4.4: Pyrazinamide
3.4.5: Fluoroquinolones
3.4.6: Bedaquiline
3.4.7: Amynoglycosides
3.4.8: Thioamides
3.4.9: Cyclic Peptides
3.5: Global Anti-Tuberculosis Therapeutics Market by End Use
3.5.1: Hospitals
3.5.2: Specialty Clinics
3.5.3: Homecare
3.5.4: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Anti-Tuberculosis Therapeutics Market by Region
4.2: North American Anti-Tuberculosis Therapeutics Market
4.2.2: North American Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
4.3: European Anti-Tuberculosis Therapeutics Market
4.3.1: European Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
4.3.2: European Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
4.4: APAC Anti-Tuberculosis Therapeutics Market
4.4.1: APAC Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
4.4.2: APAC Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
4.5: ROW Anti-Tuberculosis Therapeutics Market
4.5.1: ROW Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
4.5.2: ROW Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Type
6.1.2: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Drug Classes
6.1.3: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by End Use
6.1.4: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Region
6.2: Emerging Trends in the Global Anti-Tuberculosis Therapeutics Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Anti-Tuberculosis Therapeutics Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Anti-Tuberculosis Therapeutics Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Lupin
7.2: Macleods
7.3: Otsuka
7.4: Johnson & Johnson
7.5: Sequella
7.6: Novartis
7.7: Akorn
7.8: Fresenius SE
7.9: Viatris
